The performance of AML^lnc69 in terms of undergoing HSCT in first CR and cytogenetic/molecular risk. (A-B) KM survival curves of RFS for the of patients with pedAML receiving HSCT (A) and without receiving HSCT in the first CR (B). (C) The distribution of cytogenetic/molecular risk between low- and high-risk groups based on AML^lnc69. (D-F) KM survival curve of RFS of patients with pedAML based on AML^lnc69 in low-, standard-, and high-risk groups categorized by cytogenetic/molecular risk stratification. CR, complete remission.